TG Therapeutics, Inc.
TGTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $4,374 | $2,425 | $1,602 | $2,512 |
| - Cash | $180 | $93 | $102 | $299 |
| + Debt | $254 | $111 | $83 | $79 |
| Enterprise Value | $4,449 | $2,442 | $1,583 | $2,292 |
| Revenue | $329 | $234 | $3 | $7 |
| % Growth | 40.8% | 8,290% | -58.4% | – |
| Gross Profit | $291 | $220 | $3 | $6 |
| % Margin | 88.3% | 94% | 90.5% | 88.2% |
| EBITDA | $50 | $26 | -$213 | -$342 |
| % Margin | 15.2% | 11.2% | -7,651.9% | -5,112.4% |
| Net Income | $23 | $13 | -$224 | -$348 |
| % Margin | 7.1% | 5.4% | -8,036.3% | -5,204.1% |
| EPS Diluted | 0.15 | 0.085 | -1.46 | -2.63 |
| % Growth | 75.8% | 105.8% | 44.5% | – |
| Operating Cash Flow | -$41 | -$31 | -$176 | -$296 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$41 | -$31 | -$176 | -$296 |